Price Alert

Agios Pharmaceuticals Inc... (AGIO)

NASDAQ: AGIO · Real-Time Price · USD

36.61

-0.71 (-1.90%)

At close: Sep 25, 2025, 3:59 PM

36.60

-0.03%

After-hours: Sep 25, 2025, 05:12 PM EDT

-1.90% (1D)

Bid	35.15
Market Cap	2.13B
Revenue (ttm)	40.88M
Net Income (ttm)	650.08M
EPS (ttm)	11.29
PE Ratio (ttm)	3.24
Forward PE	-5.15
Analyst	Buy
Dividends	n/a

Ask	39.15
Volume	457,835
Avg. Volume (20D)	805,998
Open	37.23
Previous Close	37.32
Day's Range	36.43 - 37.23
52-Week Range	23.42 - 62.58
Beta	0.87
Ex-Dividend Date	n/a

About AGIO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol AGIO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for AGIO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Agios Pharmaceuticals Inc. is scheduled to release its earnings on Oct 30, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 weeks ago

-11.03%

Agios Pharmaceuticals shares are trading lower aft... Unlock content with Pro Subscription

1 month ago

+3.31%

AGIO stock has given up its prior gain. Agios Pharmaceuticals shares were trading higher amid reports of Pyrukynd patient deaths.

News

2 weeks ago · zacks.com

AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia

Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.

2 weeks ago · seekingalpha.com

Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated

Agios Pharmaceuticals, Inc. faces a three-month FDA review delay for mitapivat in thalassemia due to safety concerns, but no new efficacy or safety data was requested. Despite the setback, I remain co...

3 weeks ago · benzinga.com

FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use

On Thursday, the U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) goal date for Agios Pharmaceuticals, Inc.'s AGIO supplemental New Drug Application (sNDA) o...

1 month ago · fool.com

Agios (AGIO) Q2 Revenue Jumps 45%

Agios Pharmaceuticals (AGIO -6.15%), a biotechnology company focused on therapies for rare blood disorders, released its second quarter 2025 earnings on July 31, 2025. The headline was a notable reven...

1 month ago · seekingalpha.com

Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q2 2025 Earnings Call July 31, 2025 8:00 AM ET Company Participants Brian M. Goff - CEO & Director Cecilia Jones - Chief Financial Officer Sarah Gheuens - Ch...

1 month ago · zacks.com

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.93 per share versus the Zacks Consensus Estimate of a loss of $1.74. This compares to a loss of $1.69 per share a year ago.